21. Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data. Issue 2 (March 2014) Authors: Mills, A.; Crofoot, G.; Ortiz, R.; Rashbaum, B.; Towner, W.; Ward, D.; Brinson, C.; Kulkarni, R.; Garner, W.; Ebrahimi, R.; Cao, H.; Cheng, A.; Szwarcberg, J. Journal: HIV clinical trials Issue: Volume 15:Issue 2(2014) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
22. Synergy achieved in silver-TiO2 nanocomposites for the inhibition of biofouling on limestone. (15th August 2018) Authors: Becerra, J.; Zaderenko, A.P.; Sayagués, M.J.; Ortiz, R.; Ortiz, P. Journal: Building and environment Issue: Volume 141(2018) Page Start: 80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
23. The antitumor role of glatiramer acetate and fingolimod in neural tumor cell lines. (October 2020) Authors: Doello, K.; Mesas, C.; Perazzoli, G.; Garcıá-Fumero, R.; Quiñonero, F.; Ortiz, R. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗